

Fenoglide - (40,120 mg; Tablet, Oral)

Generic Name	Fenofibrate	Innovator	SALIX Pharma
Dosage	40,120 mg; Tablet, Oral	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	Less Than 5
Indication	Adjunct to diet in hypertriglyceridemia and to reduce elevated LDL-C, total-C, TG, and apo B, and to increase HDL-C, in primary hyperlipidemia and mixed dyslipidemia. Limitation of Use: was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes.		
Complexities	Yes		

Chronology Of Events

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Executive Summary

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Patent Status

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Launch Timelines and Competition

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.

Chronology Of Events

Please Contact <u>contact@researchdelta.com</u> to get Detailed Information.